文献速递淋巴瘤

单基因突变与接受放疗的局限期滤泡性淋巴瘤预后

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
PubMed 文献 · Br J Haematol · 2024-08-07

研究对117例接受放疗的局限期滤泡性淋巴瘤患者进行69基因靶向测序,发现CREBBP突变最常见且与无进展生存期较差相关,但经错误发现率校正后不显著,且在独立队列中未能验证。结论认为该情境下复发基因突变不能预测结局,其他生物标志物或可提供更好的预后信息。

要点

  • 117例局限期滤泡性淋巴瘤放疗患者中,CREBBP为最常见突变基因。
  • CREBBP突变与无进展生存期较差相关,但经错误发现率校正后不显著。
  • 该关联在独立队列中未能验证,复发基因突变不能预测结局。

核心结论

  • 复发基因突变在局限期滤泡性淋巴瘤放疗患者中不能预测结局。
  • 其他生物标志物或可提供更好的预后信息。

研究设计与样本

  • 对117例接受放疗的局限期滤泡性淋巴瘤患者进行69基因靶向测序,识别复发突变基因。

主要发现

  • CREBBP为最常见突变基因,CREBBP突变与无进展生存期较差相关,但经错误发现率校正后不显著。
  • 该关联在独立队列中未能验证。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hershenfeld SA, Tobin JWD, Shelton V, et al. Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy. Br J Haematol. 2024. PMID: 39112220. doi:10.1111/bjh.19698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。